Long Term Safety of 125 mg Per Day of Oral Azimilide in Patients With Implantable Cardioverter Defibrillator (ICDs)

PHASE3CompletedINTERVENTIONAL
Enrollment

330

Participants

Timeline

Start Date

October 31, 2002

Primary Completion Date

October 31, 2005

Study Completion Date

October 31, 2005

Conditions
Arrhythmias
Interventions
DRUG

azimilide dihydrochloride

oral, once daily until sponsor stopped the study

Trial Locations (86)

10025

Research Facility, New York

10029

Research Facility, New York

11212

Research Facility, Brooklyn

13797

Research Facility, Johnson City

14221

Research Facility, Williamsville

14621

Research Facility, Rochester

14642

Research Facility, Rochester

16502

Research Facility, Erie

17033

Research Facility, Hershey

17603

Research Facility, Lancaster

19104

Research Facility, Philadelphia

20010

Research Facility, Washington D.C.

21201

Research Facility, Baltimore

21204

Research Facility, Baltimore

22031

Research Facility, Fairfax

22908

Research Facility, Charlottesville

27157

Research Facility, Winston-Salem

27710

Research Site, Durham

29204

Research Site, Columbia

29425

Research Facility, Charleston

32207

Research Facility, Jacksonville

33308

Research Facility, Fort Lauderdale

33919

Research Facility, Fort Myers

36608

Research Facility, Mobile

37203

Research Facility, Nashville

38138

Research Facility, Germantown

43614

Research Facility, Toledo

45219

Research Facility, Cincinnati

53215

Research Facility, Milwaukee

54301

Research Facility, Green Bay

60153

Research Facility, Maywood

66160

Research Facility, Kansas City

72205

Research Facility, Little Rock

74104

Research Facility, Tulsa

75226

Research Facility, Dallas

75390

Research Facility, Dallas

77030

Research Facility, Houston

80910

Research Facility, Colorado Springs

84132

Research Facility, Salt Lake City

92037

Research Facility, La Jolla

95819

Research Facility, Sacramento

99204

Research Facility, Spokane

932354

Research Facility, Loma Linda

06610

Research Facility, Bridgeport

04102

Research Facility, Portland

02135

Research Facility, Boston

01805

Research Facility, Burlington

01655

Research Facility, Worcester

07059

Research Facility, Warren Township

07052

Research Facility, West Orange

Unknown

Research Facility, Bruges

Research Facility, Mont Godinne

Research Facility, Victoria

Research Facility, St. John's

Research Site, Halifax

Research Facility, Hamilton

Research Facility, Ottawa

Research Facility, Toronto

Research Facility, Montreal

Research Facility, Québec

Research Facility, Lille

Research Facility, Nantes

Research Facility, Paris

Research Facility, Pessac

Research Facility, Tours

Research Facility, Bad Bevensen

Research Facility, Berlin

Research Facility, Brandenburg

Research Facility, Coburg

Research Facility, Frankfurt

Research Facility, Freiburg im Breisgau

Research Facility, Hamburg

Research Facility, Heidelberg

Research Facility, Ludwigshafen

Research Facility, Magdeburg

Research Facility, Mannheim

Research Facility, Tübingen

Research Facility, Gdansk

Research Facility, Katowice

Research Facility, Lublin

Research Facility, Szczecin

Research Facility, Warsaw

Research Facility, Barcelona

Research Facility, Madrid

Research Facility, Málaga

Research Facility, Valencia

Sponsors
All Listed Sponsors
lead

Forest Laboratories

INDUSTRY

NCT00751738 - Long Term Safety of 125 mg Per Day of Oral Azimilide in Patients With Implantable Cardioverter Defibrillator (ICDs) | Biotech Hunter | Biotech Hunter